Selinexor with ruxolitinib demonstrated encouraging efficacy with a manageable safety profile in patients with myelofibrosis ...

Fedratinib can reduce symptoms and spleen volume in patients with myelodysplastic syndrome (MDS) or myeloproliferative neoplasms (MPNs), according to research presented at the ASH Annual Meeting 2024.

A decade after the discovery of CALR, the results are the first for a possible therapy for CALR-mutated MPNs to reach the ...

FibroBiologics (FBLG) announced the filing of a patent application covering methods for treatment of splenomegaly using a cell-based ...

Section 7 of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires integrated care ...

Splenomegaly, or an enlarged spleen, often occurs in connection with immune-related conditions and is seen in a variety of diseases, including autoimmune disorders and chronic infections.

These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources ...

This results in extramedullary hematopoiesis in other parts of the body, most notably the spleen, which is often enlarged. There are a number of therapeutic options to treat splenomegaly in ...

Detailed price information for Fibrobiologics Inc (FBLG-Q) from The Globe and Mail including charting and trades.